Trump Tariff Block: Analyst Bullish on TCS, L&T, Bajaj Auto
The US court’s recent decision to block former President Donald Trump’s tariff orders is a significant development that has the potential to change the game for Indian exporters. According to investment advisor Adarsh Nimborkar, this legal intervention marks a shift in global trade dynamics and could lead to near-term upside in select Indian stocks.
In a recent note, Nimborkar highlighted four stocks that could benefit from the US court’s decision: Tata Consultancy Services (TCS), Larsen & Toubro (L&T), Bajaj Auto, and Sun Pharma. He believes that these companies have the potential to gain from the reversal of Trump’s tariffs, which had been a major concern for Indian exporters.
TCS: A Leader in IT Services
TCS is one of the largest IT services companies in India, and Nimborkar sees the company as a potential beneficiary of the US court’s decision. The company has a significant presence in the US market, with a large client base across various industries. With the tariffs no longer in place, TCS may be able to benefit from increased demand from its US clients, leading to improved revenue growth and profitability.
L&T: A Conglomerate with Diversified Portfolio
L&T is a conglomerate with a diversified portfolio of businesses, including engineering, construction, and finance. The company has a significant presence in the US market, with a large client base across various industries. With the tariffs no longer in place, L&T may be able to benefit from increased demand from its US clients, leading to improved revenue growth and profitability.
Bajaj Auto: A Leading Two-Wheeler Manufacturer
Bajaj Auto is one of the leading two-wheeler manufacturers in India, with a significant presence in the global market. The company exports its vehicles to over 50 countries, including the US. With the tariffs no longer in place, Bajaj Auto may be able to benefit from increased demand for its vehicles in the US market, leading to improved revenue growth and profitability.
Sun Pharma: A Leading Pharmaceutical Company
Sun Pharma is one of the leading pharmaceutical companies in India, with a significant presence in the global market. The company exports its pharmaceutical products to over 100 countries, including the US. With the tariffs no longer in place, Sun Pharma may be able to benefit from increased demand for its pharmaceutical products in the US market, leading to improved revenue growth and profitability.
Stock Performance
The stock prices of TCS, L&T, Bajaj Auto, and Sun Pharma have been impacted by the US court’s decision. TCS’s stock price has risen by over 5% in the past week, while L&T’s stock price has risen by over 4%. Bajaj Auto’s stock price has risen by over 3%, and Sun Pharma’s stock price has risen by over 2%.
Conclusion
The US court’s decision to block Trump’s tariff orders is a significant development that has the potential to change the game for Indian exporters. According to investment advisor Adarsh Nimborkar, this legal intervention marks a shift in global trade dynamics and could lead to near-term upside in select Indian stocks. TCS, L&T, Bajaj Auto, and Sun Pharma are four stocks that could benefit from the US court’s decision, with the potential for improved revenue growth and profitability.
Investors may want to consider adding these stocks to their portfolios, given their potential to benefit from the reversal of Trump’s tariffs. However, it is important to conduct thorough research and consider various factors before making any investment decisions.
Source:
Note: The views and opinions expressed in this blog post are those of the author and do not necessarily reflect the views of the author’s employer or any other organization.
